Lanreotid Zentiva

Lanreotide, the active ingredient in Lanreotid Zentiva, is a somatostatin analog presented as an injectable solution for subcutaneous use. It treats acromegaly and certain neuroendocrine tumors, and is used to prevent complications of polycystic liver disease.

GNH USA supplies Lanreotid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lanreotide is used in endocrine and neuroendocrine disorders where inhibition of hormone secretion is required.

Acromegaly: reduces excess growth hormone secretion and normalizes IGF‑1 levels. Neuroendocrine tumors (e.g., carcinoid tumors): provides symptomatic control of hormone‑related flushing and diarrhea. Polycystic liver disease: helps prevent disease‑related complications by reducing cyst growth.

Lanreotide may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site reactions: pain, erythema, or induration. - Gastrointestinal disturbances: nausea, abdominal pain, or diarrhea. - Gallbladder abnormalities: biliary sludge or gallstones. - Hyperglycemia: elevated blood glucose levels. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Pancreatitis: acute inflammation of the pancreas. - Severe hyperglycemia or new‑onset diabetes mellitus. - Cardiac arrhythmias: bradycardia or conduction abnormalities. - Allergic reactions: anaphylaxis or severe skin rash.

When prescribing Lanreotide, clinicians should consider several safety and handling precautions. - Cardiovascular monitoring: assess for bradycardia or conduction disorders before initiation. - Glucose control: monitor blood glucose in diabetic or pre‑diabetic patients. - Gallbladder assessment: evaluate for gallstones or biliary sludge prior to therapy. - Thyroid function: check thyroid status as somatostatin analogs may affect hormone levels. - Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Cytochrome P450 3A4 inducers (e.g., rifampicin, carbamazepine): may reduce lanreotide exposure. - Somatostatin analogs combined with other hormonal therapies: risk of additive endocrine suppression.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: lanreotide may increase glucose levels, requiring dose adjustment. - Antiplatelet or anticoagulant drugs: potential for altered bleeding risk due to gastrointestinal effects. - Oral contraceptives: may have reduced efficacy; monitor for breakthrough bleeding.